×

Sign In

Search
Home

Abbvie to record $3.5 billion charge related to schizophrenia drug

By Thomson Reuters Jan 10, 2025 | 7:44 AM

(Reuters) – Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shreya Biswas)

Senior UK lawmaker flags concerns about Shein to LSE and regulator

Deshaun Watson ruptures Achilles again, could miss all of 2025

BofA bets on a potential Fed rate hike after jobs report, top Wall-St brokers revise forecasts

Exclusive-Western powers warn Syria over foreign jihadists in army, sources say

Ex-McKinsey partner pleads guilty to destroying records about work promoting opioids

Canada imposes sanctions on 14 Venezuelan officials

Privacy Policy
Terms Of Service

Midwest Communications, Inc.

Copyright © 2025. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.